ClinicalTrials.gg
CompletedNCT06128122Updated Jan 9, 2024

Dextrose Concentration Decline Rate in Vivo

An interventional study of Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels in Dextrose Concentration, sponsored by Dr. Dean Reeves Clinic. Completed at 1 site in United States. Open to male participants aged 69 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Dr. Dean Reeves Clinic · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
69 Years to 69 Years
Sex
Male
01

Study summary

Measuring the speed of decrease in dextrose concentration to help design more accurate in vitro studies

Read the detailed description

Rationale: In vitro studies of the potential mechanism of action of therapeutic dextrose injection commonly place human or animal cells in a dextrose (glucose) culture medium for a prolonged period of time, typically 24 hours, and expose them to high dextrose levels, typically 1-25% (1000- 25,000mg%). High glucose levels in culture media can cause cell death. Given that cellular apoptosis/death has not been shown to occur after therapeutic dextrose injection in vivo by histologic analysis, we expect that elevated glucose levels drop rapidly in vivo. In this study 12.5% dextrose will be injected intraarticularly (in the knee) and dextrose 5% will be injected subcutaneously, and dextrose level measurements will be obtained at timed intervals after each in order to produce a curve depicting the pattern and speed of decrease in dextrose levels after in vivo injection. In vitro studies can then utilize this information to alter the pattern and speed of decrease of dextrose levels to mimic in vivo conditions, and in so doing provide more useful data on potential mechanisms of therapeutic dextrose injection in soft tissue and joints.

02

Conditions studied

  • Dextrose Concentration

Keywords

  • Dextrose
  • Hydrodissection
  • Proliferation
03

In context

Lead sponsor

Dr. Dean Reeves Clinic is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
69 Years to 69 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Able to be relatively immobile for intermittent measurement of dextrose levels

Exclusion criteria

Exclusion Criteria:

Diabetic

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Dextrose injection intraarticularly and in subcutaneous tissue with timed dextrose measurements

    Step One: Injection of 30 ml of D12.5% in the knee anteromedially with knee flexed. Placement of IV catheter into the suprapatellar pouch, and secure catheter. Withdraw and analyze samples for dextrose levels at 15-minute intervals. If catheter fails, aspirate directly from suprapatellar pouch. Step Two: Inject 1-3 ml of D5W into interstitial space about a functioning Dexcom G7 sensor. Measure dextrose levels every 5 minutes on a Dexcom receiver.

    Procedure: Intrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels

Interventions

  • ProcedureIntrarticular and subcutaneous dextrose injection with timed measurement of dextrose levels

    Step one: 30 mL of 12.5%/0.1% lidocaine will be injected into the knee using an inferomedial approach. Using ultrasound guidance, a 20-gauge 2-inch I.V. catheter will be placed in the suprapatellar pouch, by which samples of synovial fluid from the pouch will be withdrawn and analyzed for glucose level. Step two: 3 mL of D5W will be injected into a marked spot on the back of the upper arm. A sensor/transmitter (Dexcom G7 Dexcom) is placed at the site of injection. The sensor/transmitter will begin providing dextrose levels at 5 minute intervals beginning one-half hour after placement of the sensor/transmitter, transmitted to a paired smart phone.

    Also known as: Glucose injection (Dextrose is the form of glucose that humans can metabolize)

06

What researchers measure

Primary outcomes

  1. Dextrose levels in synovial fluid

    Dextrose level in synovial fluid of the knee, beginning 1/2 hour after intraarticular injection

    Time frame: 0.5, 1, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, and 6.0 hours

  2. Dextrose level in subcutaneous tissue (interstitial space) in upper arm or abdomen

    Dextrose levels at time zero and every 5 minutes after injection subcutaneously

    Time frame: Continuous glucose measurement

07

Study locations

1 site
  • Kenneth Dean Reeves
    Shawnee Mission, Kansas 66205, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jan 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2023
First posted
Nov 13, 2023
StartActual
Dec 19, 2023
Primary completionActual
Jan 4, 2024
CompletionActual
Jan 8, 2024
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06128122
Lead sponsor
Dr. Dean Reeves Clinic
Responsible party
Dr. Dean Reeves (Principal Investigator, Dr. Dean Reeves Clinic) — Principal investigator
First posted
Nov 13, 2023
Start date
Dec 19, 2023
Primary completion
Jan 4, 2024
Completion
Jan 8, 2024
Last update
Jan 9, 2024

Study contacts

Kenneth D Reeves, M.D.
principal investigator · Dr. Dean Reeves Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion